PRX-105

PRX-105 is a plant-derived, PEGylated recombinant version of the human 'read-through' acetylcholinesterase splice variant (AChE-R). It acts as a bioscavenger for organophosphorus compounds, including nerve agents and pesticides, by binding and neutralizing these toxins before they can inhibit endogenous acetylcholinesterase. This mechanism helps prevent toxic accumulation of acetylcholine in the nervous system. PRX-105 has demonstrated both prophylactic and therapeutic efficacy in preclinical animal models exposed to lethal doses of organophosphate toxins. Early clinical trials have shown that intravenous administration is safe and well tolerated in healthy volunteers, with a favorable pharmacokinetic profile characterized by an extended half-life. The drug is being developed primarily for use as a countermeasure against chemical warfare agents (nerve agents) and organophosphate pesticide poisoning, with additional research exploring its potential role in neuroprotection related to Parkinson's disease[1][2][5][6].

Other names

plant-derived recombinant human acetylcholinesterasepegylated recombinant human acetylcholinesteraseAChE-R (read-through acetylcholinesterase splice variant)